Camelid Single-Domain Antibodies as Tools for Novel Target Identification in Kinetoplastid Research.

Steven Odongo, Line De Vocht, Bo-Kyung Jin, Zeng Li, Stefan Magez, Yann G-J Sterckx

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Steven OdongoDepartment of Biomedical Laboratory Technology and Molecular Biology (BLT), College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda.

Line De VochtLaboratory of Medical Biochemistry (LMB) and Infla-Med Centre of Excellence, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.

Bo-Kyung JinBrussels Center for Immunology (BCIM), Department of Bio-engineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

Zeng LiBrussels Center for Immunology (BCIM), Department of Bio-engineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

Stefan MagezBrussels Center for Immunology (BCIM), Department of Bio-engineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium. stefan.magez@vub.be.

Yann G-J SterckxLaboratory of Medical Biochemistry (LMB) and Infla-Med Centre of Excellence, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium. yann.sterckx@uantwerpen.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Camelid single-domain antibodies (sdAbs), commercially known as Nanobodies™, possess remarkable properties that render them highly suitable as versatile tools for target discovery and product development. Interestingly, despite their successful and broad deployment in life sciences, sdAbs remain heavily underutilized in the field of molecular parasitology. In this chapter, we describe how we have employed an unbiased camelid immunization strategy to discover novel diagnostic biomarkers with sdAbs. This protocol shows the potential of camelid sdAbs as powerful tools for novel target discovery in kinetoplastid research.

Indexed as

Antibodies, ProtozoanCamelidaeKinetoplastidaSingle-Domain AntibodiesAnimalsCamelids, New WorldCamelusHumansImmunizationAntibodies, ProtozoanSingle-Domain AntibodiesCamelid single-domain antibodyDiagnosisGlycolytic enzymesTrypanosomes

Identifiers

PMID41627770

DOI10.1186/s12967-014-0352-5

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.